B. Matthey
University of Cologne
14 Papers
387 Citations
B. Matthey is an academic researcher from University of Cologne. The author has contributed to research in topics: Immunotoxin & Pseudomonas exotoxin. The author has an hindex of 12, co-authored 14 publications.
Chat about Author
Papers
Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning.
A. Klimka,B. Matthey,R C Roovers,Stefan Barth,Jan-Willem Arends,Andreas Engert,Hennie R. Hoogenboom +6 more
TL;DR: A recombinant, human anti-CD30 single-chain variable fragment (scFv) antibody is set out to make, which may serve as a targeting moiety with reduced immunogenicity and more rapid tumour penetration in similar clinical applications.
Ki-4(scFv)–ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice
Stefan Barth,Michael Huhn,B. Matthey,Samir Tawadros,Roland Schnell,Timo Schinköthe,Volker Diehl,Andreas Engert +7 more
TL;DR: A new recombinant immunotoxin (rIT) is constructed using the murine anti-CD30 hybridoma Ki-4 to construct a new rIT for possible clinical use in patients with CD30+ lymphoma and is a promising candidate for further clinical evaluation.
96
•Journal Article
Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
Michael Huhn,Stephanie Sasse,Mehmet Kemal Tur,B. Matthey,Timo Schinköthe,Susanna M. Rybak,Stefan Barth,Andreas Engert +7 more
TL;DR: In this article, a new CD30 ligand-based fusion toxin (Ang-CD30L) using the human RNase angiogenin was developed for the treatment of CD30-positive malignancies.
82
An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETÁ) is a potent immunotoxin against a Hodgkin-derived cell line
A. Klimka,Stefan Barth,B. Matthey,R C Roovers,Hilmar Lemke,Hinrich P. Hansen,Jan-Willem Arends,Volker Diehl,Hennie R. Hoogenboom,Andreas Engert +9 more
TL;DR: The selected recombinant Ki-4 scFv was shown to specifically bind to an overlapping epitope on the CD30 antigen with binding kinetics similar to those of the original antibody, and is a promising candidate for further clinical evaluation in patients with Hodgkin’s lymphoma or other CD30+ malignancies.
Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
Stefan Barth,Michael Huhn,B. Matthey,Roland Schnell,Samir Tawadros,Timo Schinköthe,Johann Lorenzen,Volker Diehl,Andreas Engert +8 more
TL;DR: The findings, concerning potent anti‐tumor effects of a recombinant anti‐CD25 immunotoxin against disseminated Hodgkin's lymphoma in SCID mice reported here demonstrate that RFT5(scFv)‐ETA' might be suitable for further evaluation against Hodgkin’s lymph cancer in humans.
33